Seikagaku’s Pain Drug May Need More Tailored Indication, REMS For Approval

An FDA advisory committee will consider modifications to the indicated patient population, as well as the appropriate health professionals and settings to administer the proposed treatment for radicular leg pain.

older woman cringing with lower back, leg pain
The FDA may narrow the patient population and limit treatment sites for Seikagaku's leg pain drug. (Shutterstock)

Seikagaku Corporation may need a narrower indication and a Risk Evaluation and Mitigation Strategy limiting the providers and administration of its radicular leg pain treatment to gain US Food and Drug Administration approval.

More from US Advisory Committees

US FDA Advisory Committee Meetings In Jeopardy After Layoffs, But Some Employees Called Back

 
• By 

Most, if not all, adcomm support staff in the drug and biologic centers who handled meeting-specific tasks have been laid off, although sponsors still are preparing for the public reviews. Meanwhile, some cut FDA employees are being called back to work for "continuity of operations activities."

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US CDC Vaccines AdComm Rescheduled For April Without Influenza Vote

 

The disruption of CDC’s Advisory Committee on Immunization Practices meeting schedule adds fuel to concerns about potential alterations of the vaccine schedule raised by former FDA Commissioner Scott Gottlieb.

Senators Scrutinize US FDA Commissioner Nominee Makary Over VRBPAC Cancellation

 
• By 

Martin Makary said he would re-evaluate the topics that deserve a Vaccines and Related Biological Products Advisory Committee review, but did not commit to rescheduling the cancelled meeting on influenza vaccine strain selection.

More from Product Reviews

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.

EMA Recommends EU Approval For Averoa’s Xoanacyl And Four Other Drugs

 

The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.